Teresa Alonso-Gordoa

Medical Oncology Department Ramon y Cajal University Hospital

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 34 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

Neeraj Agarwal,Daniel Castellano,Teresa Alonso-Gordoa,Jose Angel Arranz Arija,Emeline Colomba,Gwenaelle Gravis,Loic Mourey,Stephane Oudard,Aude Fléchon,Macarena González,Pablo M. Rey,Michael T. Schweizer,Enrique Gallardo,Erica Johnston,Arjun Balar,Nadine Haddad,Adams K. Appiah,Karim Nacerddine,José M. Piulats

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters,Eric Angevin,Teresa Alonso-Gordoa,Kristoffer Rohrberg,Ignacio Melero,Begoña Mellado,Jose-Luis Perez-Gracia,Josep Tabernero,Celine Adessi,Christophe Boetsch,Carl Watson,Joseph Dal Porto,David Dejardin,Christopher Del Nagro,Valeria Nicolini,Stefan Evers,Christian Klein,Barbara Leutgeb,Pavel Pisa,Eva Rossmann,José Saro,Pablo Umana,Jehad Charo,Volker Teichgräber,Neeltje Steeghs

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S4 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S3 from Obinutuzumab Pretreatment As a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S5 from Obinutuzumab Pretreatment As a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Obinutuzumab Pretreatment As a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters,Eric Angevin,Teresa Alonso-Gordoa,Kristoffer Rohrberg,Ignacio Melero,Begona Mellado,Jose-Luis Perez-Gracia,Josep Tabernero,Celine Adessi,Christophe Boetsch,Carl Watson,Joseph Dal Porto,David Dejardin,Christopher Del Nagro,Valeria Nicolini,Stefan Evers,Christian Klein,Barbara Leutgeb,Pavel Pisa,Eva Rossmann,Jose Saro,Pablo Umana,Jehad Charo,Volker Teichgraeber,Neeltje Steeghs

CLINICAL CANCER RESEARCHno. 8 (2024): 1630-1641

Cited2Views0WOSBibtex

Supplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S2 from Obinutuzumab Pretreatment As a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Author Statistics

#Papers: 34

#Citation: 341

H-Index: 9

G-Index: 14

Sociability: 6

Diversity: 2

Activity: 4

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn